We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

BP Medications at Night Reduces Diabetes Risk

By HospiMedica International staff writers
Posted on 06 Oct 2015
Taking hypertension medication before sleep, rather than in the morning, not only lowers nighttime blood pressure (BP) but protects against new-onset diabetes, according to a new study.

Researchers at the University of Vigo (Spain) conducted a prospective study involving 2,012 hypertensive patients (976 men, 1,036 women, and average age 53) without diabetes, who were randomized via a computer-generated allocation table to ingest their prescribed hypertension medications upon awakening or at bedtime. Investigators blinded to the hypertension treatment scheme of the patients then assessed the development of new-onset diabetes. Participants were followed for a mean 5.9 years.

The results showed that 171 participants developed type 2 diabetes during follow-up. Patients of the bedtime ingestion group showed significantly lower asleep BP and significantly lower risk of new-onset diabetes, after adjustment for fasting glucose, waist circumference, asleep systolic mean BP, dipping classification, and chronic kidney disease (CKD). The researchers observed greater benefit with medications that block the renin-angiotensin-aldosterone system (RAAS), such as angiotensin receptor blockers (ARBs), ACE inhibitors, and β-blockers. The study was published on September 23, 2105, in Diabetologia.

“Medications that block the renin-angiotensin-aldosterone system, such as ARBs and ACE inhibitors, had the strongest antidiabetic effect,” concluded lead author Ramón Hermida, PhD. “The RAAS follows a circadian rhythm, becoming active during sleep. Accordingly, in addition to BP-lowering, RAAS blockade might also serve as an effective strategy to control impaired glucose and insulin tolerance.”

RAAS is a hormone system that regulates BP and fluid balance. When renal blood flow is reduced, prorenin is converted into renin, cascading the release of angiotensin II, a potent vasoactive peptide that causes increased BP. Angiotensin II also stimulates secretion of aldosterone, which increases reabsorption of sodium and excretion of potassium, increasing the volume of extracellular fluid in the body, which also increases BP. Angiotensin II and aldosterone also contribute to increased hepatic glucose release and decreased insulin sensitivity.

Related Links:

University of Vigo



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Oxidized Zirconium Implant Material
OXINIUM

Latest Critical Care News

Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time

Wearable Multiplex Biosensors Could Revolutionize COPD Management

New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias